Sheep * * * put one 3-lb. package of Campbell's Chemical Mix to 100 lbs. No. 4 salt and mix thoroughly. Put in troughs where they can have access to it at all times. When feeding dairy cows chop or bran, put ¼ teaspoonful in the chop or bran twice daily out of the 3-lb. package. For drench, mix one teaspoonful in ¾ quart of water and drench. We recommend force feeding when grain is fed—feed about 2 or 3 days before turning on clover or alfalfa." The above statements represented and suggested that the article was a remedy for the diseases of cattle and sheep, for any ill effects upon sheep and cattle resulting from eating alfalfa or clover, or upon dairy cows from eating chop or bran; and for preventing ill effects upon cattle from grazing on clover or alfalfa. The article when administered in accordance with the instructions on the label would not be effective for the treatment or prevention of any disease of sheep or cattle.

DISPOSITION: June 24, 1949. The shipper of the product having accepted service of the libel and authorized the entry of a final decree, judgment of condemnation was entered and the product was ordered destroyed.

DRUGS ACTIONABLE BECAUSE OF OMISSION OF, OR UNSATISFACTORY, INGREDIENTS STATEMENTS*

2749. Misbranding of solution of estrogenic hormone. U. S. v. 64 Bottles * * *. (F. D. C. No. 25971. Sample No. 31626-K.)

LIBEL FILED: November 4, 1948, Southern District of California.

ALLEGED SHIPMENT: On or about August 12, 1948, from Brooklyn, N. Y.

PRODUCT: 64 30-cc. bottles of solution of *estrogenic hormone* in the possession of Medi-Synth Laboratories, Inc., Los Angeles, Calif., which bottled this product from a bulk shipment consisting of 2 bottles, 2½-liter size, labeled in part "a Estradiol in Microsuspension."

LABEL, IN PART: (After repacking) "Solution Estrogenic Hormone (Aqueous Microsuspension) 20,000 International Units per cc. rated in Estrone units."

NATURE OF CHARGE: Misbranding, Section 502 (e) (2), the article was fabricated from two or more ingredients, and its label failed to bear the common or usual name of the active ingredient, "alpha-estradiol." The article was misbranded while held for sale after shipment in interstate commerce.

DISPOSITION: November 19, 1948. Medi-Synth Laboratories, Inc., claimant, having consented to the entry of a decree, judgment of condemnation was entered and the product was ordered released under bond for relabeling under the supervision of the Federal Security Agency.

2750. Misbranding of Ung. Hydrophen. U. S. v. 75 Tubes * * *. (F. D. C. No. 25711. Sample No. 41689-K.)

LIBEL FILED: November 2, 1948, Northern District of Illinois.

ALLEGED SHIPMENT: On or about September 9, 1948, by Goodwin Laboratories, Inc., from New York, N. Y.

---

*See also No. 2747.

PRODUCT: 75 1-ounce tubes of *Ung. Hydrophen* at Chicago, Ill. Examination showed that each gram of the product contained approximately 0.6 milligram of phenylmercuric nitrate and 10 milligrams of benzocaine, an analgesic drug.

LABEL, IN PART: "Ung. Hydrophen * * * An ointment of high potency; low toxicity."

NATURE OF CHARGE: Misbranding, Section 502 (e) (2), the article was fabricated from two or more ingredients, and its label failed to bear a statement of the quantity or proportion of phenylmercuric nitrate, a derivative of mercury, and the name of benzocaine, an active ingredient, contained therein.

DISPOSITION: March 9, 1949. Default decree of condemnation and destruction.

INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 2731 TO 2750

PRODUCTS

FEDERAL SECURITY AGENCY

FOOD AND DRUG ADMINISTRATION

NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

2751–2770

DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by the United States attorneys, acting upon reports submitted by the Federal Security Agency. Published by direction of the Federal Security Administrator.

PAUL B. DUNBAR, *Commissioner of Food and Drugs.*
WASHINGTON, D. C., *January 3, 1950.*

CONTENTS*

*For new drug shipped without effective application, see No. 2766; omission of, or unsatisfactory, ingredients statements, Nos. 2752, 2756, 2762, 2766; failure to bear a label containing an accurate statement of the quantity of the contents, Nos. 2752, 2764; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 2752, 2766; cosmetics, subject to the drug provisions of the Act, Nos. 2755, 2764.